Nanopore-targeted sequencing for simultaneous diagnosis of suspected sepsis and early targeted therapy

Abstract

Bloodstream infection can rapidly progress to sepsis with each delay to appropriate therapy. In particular, patients with advanced age, active cancer, hematological disease, immunocompromised status, or critical illness are prone to severe infection (1). The main characteristics of infection in these patients are extremely rapid progression and resistance to conventional broad-spectrum antibiotics. Early identification of pathogens is imperative for reducing the risk of death (2). However, standard diagnostic methods rely on culturing, which has poor sensitivity and is not suitable for atypical infections with fastidious organisms. Even with typical pathogenic microorganisms, the turnaround time ranges from 48 to 96 hours. Therefore, culturing is always too slow to guide targeted antimicrobial therapy. Based on third-generation sequencing technology, we directly incorporated a panel of microbial tags and developed nanopore-targeted sequencing (NTS). Using real-time NTS, we successfully identified pathogens under complex host-microorganism settings, such as whole blood samples. This approach can reduce testing time and clinical turnaround time to less than 2 and 6 hours, respectively, enabling early targeted therapy. The detailed protocol and evaluation of NTS have been published elsewhere as a methodological study (3,4). Briefly, instead of a metagenomic analysis, a panel of 27,668 microbial tags (including bacteria, fungi, viruses, drug-resistant genes, and atypical pathogens), were incorporated into the nanopore sequencing platform. Therefore, targeted sequencing, with full-length read and real-time analytic approaches, was developed. Pathogens with moderate-to-high abundance were reported within 2 hours after sequencing, and pathogens with low abundance were reported within 8 hours after sequencing. Thus, a total clinical turnaround time of 6 to 18 hours can be achieved. Background noise was filtered out using negative controls. The cut-off value for a positive diagnosis was 20 reads. The limit of detection was 25 colony-forming units/mL. This retrospective case series study was registered at the Chinese Clinical Trial Registry (www.chictr.org.cn, No. ChiCTR2000028904), and was approved by the Ethics Committee of the Union Hospital affiliated with the Huazhong University of Science and Technology (IRB approval ID: 2019-S316). Written informed consent was obtained from all patients to publish this study. Eleven patients with hematologic disorders who underwent NTS diagnosis between November and December 2019 were consecutively enrolled and retrospectively reviewed. Ten patients underwent hematopoietic stem cell transplantation (Table S1). In 6 patients, the procalcitonin (PCT) or C-reactive protein (CRP) levels were more than 20 ng/mL or 100 mg/L, respectively, during the first episode of fever. For each infection, routine microbiological culturing (Appendix 1) was performed at least once, while NTS was performed only once. NTS sampling was performed at the same time as the culture sampling. Traditional cultures were able to detect a pathogen in only 2 of the 11 cases. NTS identified pathogenic microorganisms or conditional pathogenic microorganisms in all 11 cases (100%), with a clinical turnaround time within 6 hours in 9 cases. According to The Sanford Guide to Antimicrobial Therapy 2018 (5), appropriate antibiotics were immediately prescribed (Appendix 1). One patient died of severe sepsis (PCT >100 ng/mL) 23 hours after the first episode of hyperpyrexia; and the CRP level in the other 10 cases decreased steadily, and the infection was completely controlled ( Table 1 ). Table 1 Results of nanopore targeted sequencing testing and clinical effect Case PCT (ng/mL) & CRP (mg/L)* Organism culture (clinical turnaround time)† NTS (clinical turnaround time) Early targeted antibiotic therapy Clinical outcome 1 51.8/198 Blood (–), 9 times First infection: Streptococcus mitis (blood, 18 h, reads 37, coverage 98.7%); Second infection: Pandoraea sputorum (blood and pharyngeal swab, 6 h, reads 1,875/1,239, coverage 97.7%/97.7%) Cefoperazone-sulbactam + daptomycin + caspofungin; followed by Imipenem + sulfamethoxazole + caspofungin Resolution after 41 days 2 1.17/116 Blood (–), 3 times Pandoraea sputorum (blood, 6 h, reads 2,260, coverage 98.1%) Imipenem + sulfamethoxazole Resolution after 10 days 3 1.22/156 Blood (–), 4 times Enterobacter cancerogenus (blood, 18 h, reads 41, coverage 97.6%) Meropenem + colistin Resolution after 10 days 4 0.3/114 Blood (–), twicesputum (–), once Escherichia coli (blood, 18 h, reads 117, coverage 97.1%) Cefoperazone-sulbactam Resolution after 5 days 5 21.05/58.2 Candida tropicalis (blood, 62 h) Candida tropicalis (blood and anal swab, 6 h, reads 72,295/4,389, coverage 99.2%/99.5%) Meropenem + caspofungin PCT increased to more than 100 ng/mL; CRP increased to 231 mg/L; Death from sepsis within 23 hours 6 0.34/117.3 B (–), 3 times Candida albicans (blood, 6 h, reads 23,112, coverage 98.7%) Micafungin Resolution after 9 days 7 0.85/25 Fecal (–) Acinetobacter baumannii (fecal and anal swab, 6 h, reads 9,892/32,430, coverage 97.7%/98.9%) Etimicin + colistin Resolution after 7 days 8 1.26/148 Pseudomonas aeruginosa (sputum, 50 h); blood (–), 6 times Escherichia coli (blood and anal swab, 6 h, reads 209, coverage 98.1%); Alcaligenes faecalis (blood, 6 h, reads 210, coverage 98.7%); Candida tropicalis (blood, 6 h, reads 4,540, coverage 97.5%) Imipenem + ciprofloxacin + caspofungin; followed by piperacillin-tazobactam + colistin + voriconazole Resolution after 21 days 9 0.82/37.5 Blood (–), twice Candida albicans (blood, 6 h, reads 27,682, coverage 97.7%) Micafungin Resolution after 11 days 10 0.17/71.2 Blood (–), twice Candida parapsilosis (blood, 6 h, reads 10,395, coverage 97.2%); Enterobacter cancerogenus (blood, 18 h, reads 78, coverage 98.9%) Meropenem + caspofungin + amphotericin B Resolution after 14 days 11 2.06/21 Blood (–), once Streptococcus oralis (blood, 6 h, reads 1,868, coverage 98.2%); Pseudomonas gessardii (blood, 6 h, reads 1,342, coverage 97.9%); Klebsiella pneumonia (blood, 18 h, reads 23, coverage 99.6%) Gentamicin + linezolid + tegacycline Resolution after 8 days The prophylactic antibiotics in this setting of HSCT for each patient are “Moxifloxacin or Gentamicin” + oral “Fluconazole or Voriconazole”. *, PCT and CRP tests at the first episode of fever; Normal levels: PCT <0.5 ng/mL, CRP <8 mg/L; †, clinical turnaround time: from sampling to report. CRP, C-reactive protein; PCT, procalcitonin; NTS, nanopore targeted sequencing. As an example, in case 1, a 15-year-old girl diagnosed with acute lymphoblastic leukemia, underwent haploidentical hematopoietic stem cell transplantation (Figure S1). Laminar-flow ward admission was used as the reference point for day 1. At first, she received preventive antimicrobial therapy (gentamicin + fluconazole + ganciclovir). After myeloablative conditioning, allogeneic transplantation of both the peripheral blood and bone marrow stem cells from a haploidentical donor (her father) was performed. Upon neutropenia, PCT and CRP levels rapidly increased to 51.8 ng/mL and 198 mg/L, respectively. Because of sepsis, broad-spectrum antibiotics were empirically administered (cefoperazone + tegacycline + caspofungin). Four days later, the first NTS was performed, which revealed a bloodstream infection with Streptococcus mitis. The inflammatory markers decreased gradually after intravenous daptomycin treatment, and she recovered after granulocyte engraftment. However, recurrent hyperpyrexia and grade 4 oral mucositis occurred 2 days later. The second NTS revealed highly abundant, multidrug-resistant Pandoraea sputorum in both blood and pharyngeal swab samples within 6 hours after sampling (Figure S2). The antimicrobial strategy was immediately replaced with imipenem combined with sulfamethoxazole. Infection was eventually controlled on day 51. No microorganisms were detected in additional NTS tests (data not shown). During the entire course of infection, no pathogens were detected in any of the 9 routine blood cultures. Third-generation sequencing technology, including the Oxford Nanopore Technologies platform, is widely employed in metagenomics studies involving animal, plant, and microorganism samples (6-9). Nanopore sequencing may overcome many shortcomings faced by next-generation sequencing as a diagnostic tool. It can generate read-by-read data with individual read lengths of tens and thousands of nucleotides, by utilizing cost-effective and real-time long-read sequencing strategy. Nanopore sequencing provides higher resolution, greater accuracy, and faster turnaround time, than do currently available commercial techniques. Therefore, its implementation in the clinical setting will markedly improve real-time point-of-care pathogen diagnosis (10-13). In one study, nanopore metagenomics was developed to enable the rapid diagnosis of bacterial lower respiratory infections using respiratory samples. Compared with culturing, the optimized method was 96.6% sensitive and 41.7% specific for bacteria detection, with a minimum turnaround time of 6 hours under experimental conditions (14). In contrast, we developed a novel NTS rather than the metagenomics method, and presented the first clinical report that real-time NTS can timely identify pathogens in whole blood samples from patients with severe infection. Targeted microbial tags enable pathogen detection in whole blood samples, a more complex host-microorganism setting, and further shorten the testing duration. In this study, NTS detected multiple pathogens including uncommon and atypical pathogens in each patient within 6 to 18 hours in a clinical context. As a result, these patients with severe infections benefited from early targeted antimicrobial therapy. Moreover, our method can be expanded to patients in different clinical settings. In conclusion, NTS is a promising approach for rapidly and accurately characterizing pathogens, and guiding antimicrobial treatment. This application should be confirmed and optimized for future clinical practice. Supplementary The article’s supplementary files as 10.21037/atm-21-2923 10.21037/atm-21-2923